Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services (Q28781): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Created a new Item) |
Superraptor (talk | contribs) (Added [en] label: Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services) |
||
| label / en | label / en | ||
Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services | |||
Revision as of 17:52, 5 November 2024
No description defined
- Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services |
No description defined |
|
Statements
The practice of hormone therapy is crucial in aligning secondary sex characteristics with the gender identity of transgender adults. (English)
This study examines the effects of a commonly used injectable hormone combination, specifically estradiol enanthate with dihydroxyprogesterone acetophenide (EEn/DHPA), on serum hormonal levels and self-reported satisfaction with breast development in transwomen. (English)
Our research focused on a retrospective longitudinal study involving a large cohort of transwomen evaluated between 2020 and 2022, comprising 101 participants. (English)
We assessed serum levels of estradiol (E2), testosterone (T), luteinizing hormone (LH), and follicle-stimulating hormone (FSH), comparing the EEn/DHPA hormonal regimen with other combined estrogen-progestogen (CEP) therapies. (English)
Additionally, a subset of 43 transwomen completed a 5-question survey to evaluate self-reported satisfaction with breast development using Tanner scales. (English)
Our findings indicated that participants using the EEn/DHPA regimen exhibited significantly higher serum E2 levels (mean: 186 pg/mL ± 32 pg/mL) than those using other therapies (62 ± 7 pg/mL), along with lower FSH levels, but no significant differences in T and LH levels. (English)
Concerning satisfaction with breast development, 76% reported increased fulfillment with breast augmentation while using EEn/DHPA. (English)
These results suggest that an injectable, low-cost EEn/DHPA administered every three weeks could serve as an alternative feminizing regimen, particularly considering the extensive long-term experience of the local transgender community. (English)
Further longitudinal studies on the efficacy of feminizing-body effects and endovascular risks of various parenteral CEP types are warranted to improve primary healthcare provision for transgender persons. (English)
Camila (English)
Toffoli Ribeiro (English)
C
Ísis (English)
Gois (English)
Í
Mariana (English)
da Rosa Borges (English)
M
Lucas Garcia Alves (English)
Ferreira (English)
LGA
Matheus (English)
Brandão Vasco (English)
M
João Guimarães (English)
Ferreira (English)
JG
Taciana Carla (English)
Maia (English)
TC
Magnus Régios (English)
Dias-da-Silva (English)
MR
25 September 2024
20 September 2024
The authors confirm that the research was carried out without any existing commercial or financial affiliations that might pose a potential conflict of interest. (English)
No potential conflict of interest was reported by the author(s). (English)